WO2014137090A1 - Préparation pour la prévention ou le traitement du diabète - Google Patents

Préparation pour la prévention ou le traitement du diabète Download PDF

Info

Publication number
WO2014137090A1
WO2014137090A1 PCT/KR2014/001455 KR2014001455W WO2014137090A1 WO 2014137090 A1 WO2014137090 A1 WO 2014137090A1 KR 2014001455 W KR2014001455 W KR 2014001455W WO 2014137090 A1 WO2014137090 A1 WO 2014137090A1
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
metformin
pharmaceutically acceptable
complications
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2014/001455
Other languages
English (en)
Inventor
Eun Ji Kim
Hye Jung Park
Sang Jun Youn
Hyo Ju PARK
Min Ju Hong
Hyo Ju Pyo
Yun Ah Jung
Hyun Wook Park
Yun Jung Kim
Geun Seog Song
Byoung Seok Moon
Kwi Man Kang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HK Inno N Corp
Original Assignee
CJ Healthcare Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CJ Healthcare Corp filed Critical CJ Healthcare Corp
Priority to JP2015559188A priority Critical patent/JP2016509065A/ja
Priority to BR112015018934A priority patent/BR112015018934A2/pt
Priority to HK16100385.5A priority patent/HK1212587A1/zh
Priority to EP14760276.7A priority patent/EP2964211A4/fr
Priority to PH1/2014/500736A priority patent/PH12014500736A1/en
Publication of WO2014137090A1 publication Critical patent/WO2014137090A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to a pharmaceutical composition for a combination therapy comprising a therapeutically effective amount of voglibose or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof for preventing or treating the diabetes in a patient with type 2 diabetes which provides substantially equivalent or increased efficacy and substantially reduced side-effects compared to the administration of metformin alone,
  • the administration of the said composition reduces glycosylated hemoglobin (HbAlc) levels, fasting and postprandial blood glucose levels and glycemic variability in an anti-diabetes drug naive patient or in a patient with early stage of type 2 diabetes, in a substantially equivalent or increased amount, compared to the administration of metformin alone for first line therapy in treating diabetes,
  • HbAlc glycosylated hemoglobin
  • the administration of the said composition reduces the frequency of hypoglycemia, cardiovascular complications and gastrointestinal complications in an anti-diabetes drug naive patient or in a patient with early stage of type 2 diabetes, compared to the administration of metformin alone,
  • voglibose or a pharmaceutically acceptable salt thereof is present in an amount of 0.2 mg to 0.3 mg and metformin or pharmaceutically acceptable salt thereof is present in an amount of 250 mg to 1000 mg,
  • composition for a combination therapy is formulated as a single dosage form together with at least one pharmaceutically acceptable carrier,
  • the said pharmaceutical composition is administered to a patient once to five times daily, at least the minimum amount required to regulate the blood glucose level.
  • Non-insulin-dependent diabetes is one of the most common metabolic disorders and its worldwide prevalence is estimated to be 5%. The total number of people with diabetes is expected to double within the next 10 years.
  • the pathogenesis of type 2 diabetes is characterized by impaired insulin secretion and insulin resistance. Insulin resistance may cause over-secretion of insulin from the pancreatic beta cells, leading to hyperinsulinemia. Hyperinsulinemia exists before diagnosis of diabetes and functions as an independent risk factor for various other diseases. This can eventually lead to impaired beta-cell functions which cause a lack of insulin, resulting in diabetes characterized by impaired glucose tolerance after eating and impaired fasting glycemia.
  • the long-term effects of diabetes cause various chronic complications including microvascular complications such as retinopathy, neuropathy, or renopathy, or macrovascular complications such as cardiovascular, cerebrovascular or peripheral vascular complications. These chronic complications reduce quality of life in diabetic patients and greatly increase risk of death. Therefore, management of type 2 diabetes is necessary to prevent chronic complications, that is, to retard the occurrence and progression of the chronic complications.
  • microvascular complications such as retinopathy, neuropathy, or renopathy
  • macrovascular complications such as cardiovascular, cerebrovascular or peripheral vascular complications.
  • Diabetic patients having the risk of chronic complications associated with diabetes must attend strict diabetes management programs to keep their glycosylated hemoglobin (HbA1c) level at a normal level or as close to normal as possible until satisfactory metabolic control is achieved.
  • HbA1c glycosylated hemoglobin
  • the results of the Diabetes Control and Complication Trial and United Kingdom Prospective Diabetes Study (UKPDS) show that intensive blood glucose control reduces the risk of chronic complications associated with diabetes. In clinical practice, however, many patients with type 2 diabetes fail to maintain their blood glucose levels to be below the target range recommended by American Diabetes Association.
  • the analysis results of UKPDS show that failure of single therapy of oral hypoglycemic agents increases over time. Thus, it is necessary to conduct combination therapy with other drugs for more effective blood glucose control.
  • selection of appropriate drug combinations may differ depending on a subject’s conditions, but a combination of drugs with different mechanisms of action is preferred to bring about their synergistic effect.
  • combination of an alpha-glucosidase inhibitor and a biguanide-based drug is ideal in terms of simultaneously controlling two pathological mechanisms of type 2 diabetes: the elevation of blood sugar after eating and insulin resistance.
  • administration of the formulation of two or more active ingredients shows effective pharmacological action, there is a problem in that the active ingredients may exacerbate side-effects, cause adverse events, and increase the risk of complications compared to single administration.
  • a composition for a combination therapy of voglibose or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof can be provided for the reduction, in a substantially equivalent or increased amount compared to single administration of metformin, of HbAlc levels, fasting and postprandial blood glucose levels and glycemic variability and also for the reduction of the frequency of hypoglycemia, cardiovascular complications, and gastrointestinal complications in a patient with no prior experience of anti-diabetes medication or in a patient in the early stage of type 2 diabetes showing the HbAlc(%) level of 7 to 11% and ultimately, the formulation is provided for treating diabetes in patients in the early stage of type 2 diabetes and reducing or minimizing adverse events, side-effects, and the risk of complications, thereby completing the present invention.
  • An object of the present invention is to provide a composition for a combination therapy comprising voglibose or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof which is provided for the reduction, in substantially equivalent or increased amount compared to single administration of metformin, of HbAlc levels, fasting and postprandial blood glucose levels and glycemic variability and also the reduction of the frequency of hypoglycemia, cardiovascular complications, and gastrointestinal complications in a patient with no prior experience of anti-diabetes medication or a patient in the early stage of type 2 diabetes showing the HbAlc (%) level of 7 to 11% and ultimately, is able to effectively treat diabetes in patients in the early stage of type 2 diabetes and to minimize adverse events, side-effects, and the risk of complications.
  • Another object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of diabetes which comprises i) voglibose or a pharmaceutically acceptable salt thereof and ii) metformin or a pharmaceutically acceptable salt thereof and minimizes hypoglycemia, gastrointestinal complications and cardiovascular complications.
  • Still another object of the present invention is to provide a pharmaceutical composition for the prevention or improvement of cardiovascular complications, comprising i) voglibose or a pharmaceutically acceptable salt thereof and ii) metformin or a pharmaceutically acceptable salt thereof.
  • Still another object of the present invention is to provide a formulation for a combination therapy for the prevention or treatment of diabetes in a patient with type 2 diabetes, which comprises i) voglibose or a pharmaceutically acceptable salt thereof and ii) metformin or a pharmaceutically acceptable salt thereof and minimizes hypoglycemia, gastrointestinal complications and cardiovascular complications, in which the patient with type 2 diabetes has the glycosylated hemoglobin (HbAlc) of 7 to 11% and the patient has the glycosylated hemoglobin of 6 to 7% at 24 weeks after administration of the formulation.
  • HbAlc glycosylated hemoglobin
  • Still another object of the present invention is to provide a formulation for a combination therapy comprising (i) voglibose of 0.2 mg, and (ii) metformin hydrochloride of 250 mg for the improvement of one or more gastrointestinal complications selected from the group consisting of diarrhea, nausea, upper abdominal pain, periodontitis, flatulence and abdominal distension of diabetic patients.
  • a composition for a combination therapy comprising voglibose or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof according to the present invention is provided for the reduction, in a substantially equivalent or increased amount compared to single administration of metformin, of HbAlc levels, fasting and postprandial blood glucose levels and glycemic variability and also the reduction of the frequency of hypoglycemia, cardiovascular complications, and gastrointestinal complications in a patient with no prior experience of anti-diabetes medication or a patient in the early stage of type 2 diabetes showing the HbAlc (%) level of 7 to 11%, and ultimately, is able to effectively treat diabetes in patients in the early stage of type 2 diabetes and to minimize adverse events, side-effects, and risk of complications.
  • FIG. 1 is a graph showing changes from baseline in HbA1c levels after 24 weeks according to one Experimental Example of the present invention
  • FIG. 2 is a graph showing changes from baseline in FPG (mg/dL) levels after 4 weeks, 8 weeks, 12 weeks, 18 weeks, and 24 weeks according to one Experimental Example of the present invention
  • FIG. 3 is a graph showing glycemic variability from baseline using self-monitored blood glucose levels after 8 weeks, 18 weeks, and 24 weeks according to one Experimental Example of the present invention.
  • FIG. 4 is a graph showing the number of the subjects whose blood glucose levels were controlled in the target range according to one Experimental Example of the present invention.
  • the present invention provides a pharmaceutical composition for a combination therapy comprising a therapeutically effective amount of voglibose or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof for preventing or treating the diabetes in a patient with type 2 diabetes which provides substantially equivalent or increased efficacy and substantially reduced side-effects compared to the administration of metformin alone, wherein the administration of the said composition reduces glycosylated hemoglobin (HbAlc) levels, fasting and postprandial blood glucose levels and glycemic variability in an anti-diabetes drug naive patient or in a patient with early stage of type 2 diabetes, in a substantially equivalent or increased amount, compared to the administration of metfrmin alone for first line therapy in treating diabetes, wherein the administration of the said composition reduces the frequency of hypoglycemia, cardiovascular complications and gastrointestinal complications in an anti-diabetes drug naive patient or in a patient with early stage of type 2 diabetes, compared to the administration of metformin alone
  • the glycosylated hemoglobin (HbAlc) level of the patient in the early stage of type 2 diabetes is 7 to 11%
  • the fasting and postprandial glycosylated hemoglobin levels of the patient are 6 to 7% at 24 weeks after administration of the formulation
  • M-value as the index of glycemic variability is 8.20 ⁇ 1.01.
  • composition according to the present invention may be used for a combination therapy, and the composition may comprise a therapeutically effective amount of voglibose or a pharmaceutically acceptable salt thereof, and metformin or a pharmaceutically acceptable salt thereof, in combination.
  • 'voglibose' means a compound having the structure of the following Chemical Formula 1 as a therapeutic agent used for improving postprandial hyperglycemia of diabetes.
  • the voglibose may be isolated from a natural source, or prepared by obtaining it from the natural source and then chemically modifying it, or chemically synthesized by a synthetic method known in the art. Alternatively, a commercially available product may be purchased and used.
  • the voglibose or a pharmaceutically acceptable salt thereof is comprised in the composition of the present invention in an amount of 0.2 mg to 0.3 mg.
  • 'metformin' means a compound having the structure of the following Chemical Formula 2 as a compound used for prevention or treatment of non-insulin dependent diabetes.
  • the metformin may be separated from a natural source, or prepared by obtaining it from the natural source and then chemically modifying it, or chemically synthesized by a synthetic method known in the art. Alternatively, a commercially available product may be purchased and used.
  • the metformin or a pharmaceutically acceptable salt thereof may be preferably comprised in the composition of the present invention in an amount of 250 mg to 1000 mg, and more preferably, in an amount of 250 mg or 500 mg.
  • the term 'pharmaceutically acceptable salt' is a substance that does not impair biological activities and physical properties of the active ingredient to be administered, and comprise acids which form non-toxic acid addition salts containing pharmaceutically acceptable anions, for example, acid addition salts formed by inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid or the like, organic carbon acids such as tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid, salicylic acid or the like, sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid or the like.
  • inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid,
  • the pharmaceutically acceptable carboxylic acid salts comprise metal salts or alkali earth metal salts formed by lithium, sodium, potassium, calcium, magnesium or the like, amino acid salts of lysine, arginine, guanidine or the like, organic salts such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, diethanolamine, choline, triethylamine or the like.
  • the metformin may be metformin hydrochloride.
  • the term 'substantially equivalent or increased efficacy' means that HbAlc levels, fasting and postprandial blood glucose levels and glycemic variability are reduced, compared to individual treatment of active ingredients which are those comprised in the composition of the preset invention, for example, single administration of metformin, when a patient with no prior experience of anti-diabetes medication or a patient in the early stage of type 2 diabetes is treated.
  • substantially equivalent or increased efficacy compared to single administration of metformin means that the HbAlc levels are reduced to 6 to 7%, the fasting blood glucose levels are reduced to 115 to 120 mg/dL, the postprandial blood glucose levels (blood glucose level after 2 hours) are reduced to 165 to 170 mg/dL, the average blood glucose levels by self-monitoring of blood glucose are reduced to 130 to 135 mg/dL, and glycemic variability (M-value) is reduced to 8.20 ⁇ 1.01 at 24 weeks after administration of the composition of the present invention.
  • composition according to the present invention is characterized in that hypoglycemia and gastrointestinal complications are substantially reduced.
  • the sentence 'hypoglycemia and gastrointestinal complications are substantially reduced' means that frequency of hypoglycemia and gastrointestinal complications such as diarrhea, nausea, vomit, dyspepsia, constipation, periodontitis, flatulence, abdominal pain or abdominal distension caused by the use of anti-diabetic drugs is reduced, compared to patients administered with each of the active ingredients comprised in the composition of the present invention in isolation, for example, single administration of metformin.
  • the terms of 'complication' and 'side effect' are interchangeable with each other in the present invention.
  • Hypoglycemia refers to a pathologic state produced by a lower blood glucose level than normal. Most frequently, it can be caused by oral hypoglycemic agents or insulin used in the treatment of diabetes. Excessive doses of oral hypoglycemic agents or insulin, or administration at inappropriate times may cause blood sugar imbalance, leading to hypoglycemia.
  • Combination therapy of anti-diabetic drugs can trigger a drastic drop of blood glucose due to a synergistic effect, compared to single therapy. Thus, frequency of hypoglycemia generally increases.
  • voglibose and metformin as active ingredients of the present invention have different mechanisms of action, it is expected that the risk of the hypoglycemia side effect is further increased due to blood glucose lowering effects thereof upon administration of the formulation.
  • composition of the present invention has an effect of reducing the frequency of hypoglycemia side effect, compared to single administration of metformin.
  • a formulation comprising voglibose (0.2 mg) and metformin (250 mg or 500 mg) and a control group metformin (500 mg) were administered, and glycemic variability and frequency of side effects were examined for 24 weeks as an efficacy and safety test. From the result, it was confirmed that the formulation of the present invention showed a lower M-value by 4.20 (glycemic variability index) than single administration of metformin, and thus the blood glucose levels could be maintained with a small deviation. Also, the frequency of side effects was further reduced. Accordingly, it can be seen that the composition of the present invention is able to effectively regulate the blood glucose levels of diabetes patients, and therefore, side effects such as hypoglycemia due to failure of blood sugar regulation can be minimized.
  • voglibose is an alpha-glucosidase inhibitor.
  • Alpha-glucosidase is an enzyme present in the brush border of the small intestine, and functions to break down the ingested carbohydrate into monosaccharide that can be easily absorbed by the intestine. Therefore, the alpha-glucosidase inhibitor voglibose inhibits degradation of polysaccharides in the small intestine to delay digestion and absorption of complex carbohydrates, thereby inhibiting postprandial hyperglycemia and reducing hyperinsulinemia.
  • complex carbohydrates are mostly digested in the upper small intestine and do not reach the lower small intestine. Generally, less alpha-glucosidase activity is present in the ileum.
  • metformin is a hypoglycemic agent that reduces hyperglycemia to the normal blood glucose level but does not reduce the blood glucose level in non-diabetic persons. Its blood glucose-lowering mechanism has not been completely revealed yet, but some studies reported that metformin increases insulin receptor activation to improve insulin receptor-tyrosine kinase activity and to stimulate glucose transport into adipocytes and skeletal muscles. The most common side effect of metformin administration is a digestive disorder, and is observed in approximately 30% of metformin-administrated patients. General side effects of metformin are loss of appetite, nausea, abdominal discomfort, diarrhea or the like.
  • both voglibose, an alpha-glucosidase inhibitor, and metformin cause gastrointestinal complications as major side effects.
  • combination administration of these two drugs may cause more severe gastrointestinal complications.
  • the previous studies also reported that combination administration of alpha-glucosidase inhibitor and metformin remarkably increased gastrointestinal complications ( ⁇ -glycosidase inhibitors and their use in clinical practice, Arch Med Sci 2012; 8, 5:899-906).
  • the present inventors found that the formulation of voglibose and metformin of the present invention reduces frequency of gastrointestinal complications, compared to single administration of metformin, in contrast with the above studies.
  • a formulation of voglibose (0.2 mg) and metformin (250 mg or 500 mg) and a control group metformin (500 mg) were administered, respectively, and then frequency of gastrointestinal complications was examined for 24 weeks as the safety test. From the result, it was confirmed that dyspepsia, diarrhea and vomit were observed as the major gastrointestinal complications of the formulation of the present invention and metformin, and the formulation of the present invention showed significantly low frequency of gastrointestinal complications, compared to metformin.
  • the formulation for a combination therapy comprising voglibose or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof according to the present invention is characterized in that it minimizes cardiovascular complications.
  • Diabetes means a state in which the insulin action and the blood glucose levels are not properly controlled, and is characterized by high glycemic variability, compared to non-diabetic patients. Therefore, in typical methods of diabetes management, control of blood glucose greatly affects acute and chronic complications of diabetes. In particular, the diabetic complications caused by failure of blood glucose control damage small and large blood vessels in the body, resulting in impairment of blood circulation of the retina, kidney, arms and legs and various other diseases.
  • Any abnormalities in the large blood vessels may cause heart attack, angina, myocardial infarction, heart failure, diabetic dementia or the like, and any abnormalities in the small blood vessels may cause impairments in the retina, kidney, nerve or the like, leading to disease such as chronic renal failure, retinopathy, loss of eyesight or the like.
  • the glycemic variability is quantification of the amplitude of glycemic excursion, and MAGE (Mean Amplitude of Glycemic Excursion) refers to differences between the highest and lowest levels of blood glucose for one day.
  • composition of the present invention effectively reduces the amplitude of glycemic excursion so as to minimize cardiovascular complications which may occur as a diabetic complication or side effect.
  • the composition of the present invention when administered to a patient in the early stage of type 2 diabetes having HbAlc (%) level of 7 to 11%, the patient may have the HbAlc (%) level of 6 to 7% and the M-value (glycemic variability index) of 8.20 ⁇ 1.01 after 24 weeks.
  • the group treated with the formulation of the present invention showed the HbAlc levels of -1.62 ⁇ 0.07%, compared to the baseline, and the group treated with the single formulation of metformin showed the HbAlc levels of -1.31 ⁇ 0.07%, compared to the baseline.
  • M-value ⁇ [10 * log(blood glucose/100]3 ⁇ /n+ ⁇ Max(blood glucose)-Min(blood glucose) ⁇ /20
  • the average blood glucose level was 133.08 ⁇ 2.32 mg/dL, which was approximately -9.48 mg/dL reduction, compared to 142.56 ⁇ 2.35 mg/dL of the single administration of metformin.
  • the M-value after administration of the formulation of the present invention was 8.20 ⁇ 1.01, which is approximately -4.20 reduction, compared to 12.40 ⁇ 1.03 of the single administration of metformin. Accordingly, it was confirmed that the formulation according to the present invention effectively controls the blood glucose without a significant variability so as to minimize side-effects of cardiovascular diseases.
  • blood glucose levels that is, blood glucose levels within 2 hours of eating, are a more important risk factor of cardiovascular complications than the amplitude of glycemic excursion.
  • composition of the present invention is able to effectively inhibit elevation of postprandial blood glucose (PPG, post plasma glucose).
  • PPG postprandial blood glucose
  • composition for a combination therapy comprising voglibose or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof according to the present invention provides an effect of reducing the substantially equivalent or increased body weight and an effect of increasing body weight substantially reduced, compared to single administration of metformin.
  • Obesity is a major cause of diabetes, because the adipose tissue in obese people is insulin resistant, resulting in uncontrolled blood glucose. For this reason, patients with obesity are the highest percentage of patients with diabetes. In US, it was reported that 60% or more of diabetic patients, that is, 6 out of 10, are obese. In Korea, 40% ⁇ 50% of diabetic patients are also obese.
  • Diabetic patients have rapid weight loss in the early stages, but gradually gain weight with blood glucose control.
  • most anti-diabetic agents including insulin increase body weight. The exact cause has not been revealed but insulin regulation is suggested as one of the causes. Specifically, if anti-diabetic agents do not provide insulin at the exact time of insulin-deficiency, insulin can be abused, and therefore, excessive insulin stimulates lipogenesis and inhibits lipolysis, resulting in obesity.
  • body weight control is also important in patients who are already diabetic, because body weight control of diabetic patients prevents diabetes complications. In particular, vascular complications can be prevented. Thus, it is important to control the body weight of the patients in the early stage of diabetes.
  • anti-diabetic agents to prevent weight gain as well as to control blood glucose, and furthermore to reduce body weight, can be key therapeutic agents capable of breaking the vicious circle of diabetes and obesity.
  • composition of the present invention has the effects of effectively suppressing body weight gain and furthermore reducing body weight.
  • a formulation comprising voglibose (0.2 mg) and metformin (250 mg or 500 mg) and a control group metformin (500 mg) were administered, respectively and changes in body weight were examined for 24 weeks.
  • the formulation of the present invention showed the body weight loss of -1.63 ⁇ 2.25 kg, and the single formulation of metformin showed the body weight loss of -0.86 ⁇ 2.52 kg, compared to the baseline, indicating the formulation of the present invention is effective for body weight loss.
  • composition of the present invention can be used for the patients in the early stage of type 2 diabetes whose blood glucose is not sufficiently controlled by diet and exercise, and in particular, it can be used in anti-diabetes drug naive patient or in a patient with early stage of type 2 diabetes.
  • the patients in the early stage of type 2 diabetes may have HbAlc(%) levels of 7 to 11%.
  • composition of the present invention is characterized in that it is able to minimize the risk of gastrointestinal complications and cardiovascular complications, and its overall adverse reactions related to drug treatment are less than the conventional anti-diabetic agents.
  • the composition of the present invention may comprise voglibose or a pharmaceutically acceptable salt thereof in an amount of 0.2 to 0.3 mg and metformin or a pharmaceutically acceptable salt thereof in an amount of 250 to 1000 mg, and more preferably, voglibose or a pharmaceutically acceptable salt thereof in an amount of 0.2 mg and metformin or a pharmaceutically acceptable salt thereof in an amount of 250 mg or 500 mg.
  • the formulation of the present invention may be formulated by further using typical additives such as a pharmaceutically acceptable diluent, binder, disintegrating agent, lubricant, pH adjuster, anti-foaming agent, solubility enhancer or the like within the range of not deteriorating the effects of the present invention.
  • typical additives such as a pharmaceutically acceptable diluent, binder, disintegrating agent, lubricant, pH adjuster, anti-foaming agent, solubility enhancer or the like within the range of not deteriorating the effects of the present invention.
  • composition of the present invention may be prepared into various formulations, for example, tablets such as uncoated tablet, film-coated tablet, single layer tablet, double layer tablet, multi-layer tablet, or core tablets, powder, granules, capsules or the like.
  • the composition may be formulated into a single dosage form, together with at least one pharmaceutically acceptable carrier.
  • the composition may be administered once to five times a day, and more preferably, three times a day between meals on an empty stomach up to the minimum effective daily dosage needed for proper blood glucose regulation.
  • composition of the present invention thus prepared can be effectively used for the prevention and treatment of diabetes or diabetes complications as a hypoglycemic agent for minimizing hypoglycemia, gastrointestinal complications and cardiovascular complications in the patients in the early stage of type 2 diabetes.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising i) voglibose or a pharmaceutically acceptable salt thereof and ii) metformin or a pharmaceutically acceptable salt thereof for the prevention or treatment of diabetes, in which hypoglycemia, gastrointestinal complications and cardiovascular complications are minimized.
  • voglibose metformin
  • pharmaceutically acceptable salts thereof hypoglycemia, gastrointestinal complications, and cardiovascular complications are the same as described above.
  • the pharmaceutical composition has an effect of reducing body weight or suppressing body weight gain.
  • the effect of reducing body weight or suppressing body weight gain is the same as described above.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising i) voglibose or a pharmaceutically acceptable salt thereof and ii) metformin or a pharmaceutically acceptable salt thereof for the prevention or improvement of cardiovascular complications.
  • voglibose, metformin, and pharmaceutically acceptable salt are the same as described above.
  • the cardiovascular complications refer to those caused by type 2 diabetes, and specifically, refer to complications caused by blood vessel damages in the body and impairment of blood circulation due to failure in blood glucose control.
  • the cardiovascular complications may be diseases such as heart attack, angina, myocardial infarction, heart failure, diabetic dementia, chronic renal failure, retinopathy, loss of eyesight or the like.
  • the present invention provides a formulation comprising i) voglibose or a pharmaceutically acceptable salt thereof and ii) metformin or a pharmaceutically acceptable salt thereof for the prevention or treatment of diabetes in a patient with type 2 diabetes, which is characterized in that hypoglycemia, gastrointestinal complications and cardiovascular complications are minimized, and in which the glycosylated hemoglobin (HbAlc) level of the patient with type 2 diabetes is 7 to 11%, the glycosylated hemoglobin level of the patient is 6 to 7% at 24 weeks after administration of the formulation.
  • HbAlc glycosylated hemoglobin
  • voglibose, metformin, pharmaceutically acceptable salt, hypoglycemia, gastrointestinal complications, cardiovascular complications are the same as described above.
  • the glycemic variability index M-value of the patient at 24 weeks after administration of the formulation is 8.20 ⁇ 1.01.
  • the glycemic variability index M-value is the same as described above.
  • the pharmaceutical composition has an effect of reducing body weight or suppressing body weight gain.
  • the effect of reducing body weight or suppressing body weight gain is the same as described above.
  • the present invention provides a formulation comprising (i) voglibose of 0.2 mg and (ii) metformin hydrochloride of 250 mg for the improvement of one or more gastrointestinal complications selected from the group consisting of diarrhea, nausea, upper abdominal pain, periodontitis, flatulence, and abdominal distension of diabetic patients.
  • voglibose, metformin, and gastrointestinal complications are the same as described above.
  • the formulation can further improve cardiovascular complications.
  • the cardiovascular complications are the same as described above.
  • the formulation can further improve hypoglycemia side effect.
  • the hypoglycemia side effect is the same as described above.
  • the present invention provides a method for alleviating hypoglycemia, gastrointestinal complications and cardiovascular complications, comprising the step of administering the composition or the formulation to a subject in need thereof.
  • composition or the formulation, hypoglycemia, gastrointestinal complications and cardiovascular complications are the same as described above.
  • the present invention provides a method for preventing or treating diabetes, comprising the step of administering the composition or the formulation to a subject in need thereof, in which hypoglycemia, gastrointestinal complications and cardiovascular complications are minimized.
  • composition or the formulation, hypoglycemia, gastrointestinal complications, cardiovascular complications, and diabetes are the same as described above.
  • the present invention provides the use for the alleviation or improvement of hypoglycemia, gastrointestinal complications and cardiovascular complications in the preparation of the composition or the formulation for a combination therapy comprising i) voglibose or a pharmaceutically acceptable salt thereof and ii) metformin or a pharmaceutically acceptable salt thereof.
  • the present invention provides the use for the prevention or treatment of diabetes for minimizing hypoglycemia, gastrointestinal complications and cardiovascular complications in the preparation of the composition or the combined comprising i) voglibose or a pharmaceutically acceptable salt thereof and ii) metformin or a pharmaceutically acceptable salt thereof.
  • Example 2 The granules prepared in Example 1 were mixed with 3 g of magnesium stearate as a lubricant for a proper time, and then 585.3 ⁇ 30 mg thereof was press-molded to prepare oval tablets. Each tablet contained 500 mg of metformin hydrochloride and 0.3 mg of voglibose in average.
  • Example 2 The granules prepared in Example 2 were mixed with 3 g of magnesium stearate as a lubricant for a proper time, and then 585.3 ⁇ 30 mg thereof was press-molded to prepare oval tablets. Each tablet contained 500 mg of metformin hydrochloride and 0.2 mg of voglibose in average.
  • Example 3 The granules prepared in Example 3 were mixed with 3 g of magnesium stearate as a lubricant for a proper time, and then 292.8 ⁇ 15 mg thereof was press-molded to prepare oval tablets. Each tablet contained 250 mg of metformin hydrochloride and 0.3 mg of voglibose in average.
  • Example 2 The granules prepared in Example 1 were mixed with 3 g of magnesium stearate as a lubricant for a proper time, and then 292.8 ⁇ 15 mg thereof was press-molded to prepare oval tablets. Each tablet contained 250 mg of metformin hydrochloride and 0.2 mg of voglibose in average.
  • CJ-30001 containing 0.2 mg of voglibose/500 mg of metformin hydrochloride and CJ-30002 containing 0.2 mg of voglibose/250 mg of metformin hydrochloride prepared in the same manner as in Example 6 or 8 were orally administered for 24 weeks to patients with type 2 diabetes whose blood glucose levels were not properly controlled, in order to evaluate whether their blood glucose-lowering effects were superior to those of metformin administration alone.
  • the selection criteria and the exclusion criteria are as follows.
  • CJ-30001 (formulation of 0.2 mg of voglibose and 500 mg of metformin hydrochloride) and CJ-30002 (formulation of 0.2 mg of voglibose and 250 mg of metformin hydrochloride) were used as test drugs.
  • CJ-30002 was orally administered at an initial dose three times a day before meals. If the insufficient blood glucose-controlling effect was observed, the dose was increased with administration of CJ-30001 three times a day.
  • Glucophage ® tablet 500 mg of metformin hydrochloride was orally administered as a control drug at an initial dose of 1000 mg three times a day before meals. If the insufficient blood glucose-controlling effect was observed, the dose was increased to 1500 mg three times a day.
  • the total administration period was 24 weeks (168 days).
  • Adverse events and adverse drug reactions were summarized to present frequency and 95% confidence interval. Further, the differences before and after administration between the two administration groups were compared and analyzed by unpaired t-test or Wilcoxon's rank sum test.
  • CJ-30001/CJ-30002 showed superior HbA1c-lowering effect at 24 weeks after oral administration compared to metformin.
  • FIG. 2 shows changes in FPG (mg/dL) from baseline to 4 weeks, 8 weeks, 12 weeks, 18 weeks, and 24 weeks.
  • FPG FPG
  • FIG. 3 shows changes in glycemic variability using self-monitored blood glucose levels from baseline to 8 weeks, 18 weeks, and 24 weeks. As shown in FIG. 3, there was a significant difference in glycemic variability between CJ-30001/CJ-30002 and metformin groups.
  • FIG. 4 demonstrates the number of subjects whose blood glucose levels were controlled within the target range.
  • HbA1c, FPG or 2h-PPG levels were controlled to below the target level(HbA1c less than 6.5% or 7%, FPG less than 126 mg/dL, and 2h-PPG less than 200 mg/dL) in CJ-30001/CJ-30002 group after 24 weeks, compared to metformin group.
  • CJ-30001/CJ-30002 group had a larger number of the subjects whose blood glucose levels reached the target range.
  • the frequencies of adverse events in the CJ-30001/CJ-30002 group and metformin group were 154 and 189 cases, respectively, with no statistically significant difference between the two groups.
  • Most of the mild adverse events that occurred in both groups were gastrointestinal adverse events.
  • the most frequent drug related gastrointestinal adverse events were dyspepsia (25 cases) in CJ-30001/CJ-30002 group and diarrhea (37 cases) in metformin group.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une préparation de voglibose ou de son sel pharmaceutiquement acceptable et de metformine ou de son sel pharmaceutiquement acceptable qui est proposée pour la réduction, en quantité sensiblement équivalente ou accrue par comparaison à l'administration unique de metformine, des taux de HbAlc, des taux de glycémie à jeun et postprandiale et de la variation de la glycémie postprandiale, ou de la variabilité glycémique ainsi que la réduction de la fréquence des hypoglycémies, des complications cardiovasculaires et des complications gastro-intestinales chez un patient sans expérience préalable de traitement antidiabétique ou chez un patient au stade précoce de diabète de type 2 présentant un taux de HbAlc (%) de 7 à 11 %. Finalement, la préparation de la présente invention permet de traiter de façon efficace le diabète chez des patients au stade précoce de diabète de type 2 et de réduire au maximum les effets indésirables, les effets secondaires et le risque de complications.
PCT/KR2014/001455 2013-03-06 2014-02-24 Préparation pour la prévention ou le traitement du diabète Ceased WO2014137090A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2015559188A JP2016509065A (ja) 2013-03-06 2014-02-24 糖尿病の予防又は治療のための製剤
BR112015018934A BR112015018934A2 (pt) 2013-03-06 2014-02-24 formulação para a prevenção ou tratamento de diabetes
HK16100385.5A HK1212587A1 (zh) 2013-03-06 2014-02-24 用於预防或者治疗糖尿病的制剂
EP14760276.7A EP2964211A4 (fr) 2013-03-06 2014-02-24 Préparation pour la prévention ou le traitement du diabète
PH1/2014/500736A PH12014500736A1 (en) 2013-03-06 2014-02-24 Formulation for prevention or treatment of diabetes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2013-0024157 2013-03-06
KR1020130024157A KR101336499B1 (ko) 2013-03-06 2013-03-06 당뇨병의 예방 또는 치료용 복합 조성물

Publications (1)

Publication Number Publication Date
WO2014137090A1 true WO2014137090A1 (fr) 2014-09-12

Family

ID=49987171

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2014/001455 Ceased WO2014137090A1 (fr) 2013-03-06 2014-02-24 Préparation pour la prévention ou le traitement du diabète

Country Status (9)

Country Link
EP (1) EP2964211A4 (fr)
JP (1) JP2016509065A (fr)
KR (1) KR101336499B1 (fr)
CN (1) CN104027328A (fr)
BR (1) BR112015018934A2 (fr)
HK (1) HK1212587A1 (fr)
PH (1) PH12014500736A1 (fr)
TW (1) TW201434463A (fr)
WO (1) WO2014137090A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026000747A1 (fr) * 2024-06-26 2026-01-02 四川大学华西医院 Système de prédiction de diabète et d'hypertension basé sur un signal électrique gastro-intestinal et procédé de construction

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101189639B1 (ko) * 2008-12-15 2012-10-12 씨제이제일제당 (주) 메트포르민 및 α-글리코시다제 억제제를 포함하는 경구 제제 및 그 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US20080207490A1 (en) * 2005-07-07 2008-08-28 Postech Foundation Glucose Uptake Modulator and Method for Treating Diabetes or Diabetic Complications
CN101590007A (zh) * 2008-05-27 2009-12-02 北京瑞伊人科技发展有限公司 一种盐酸二甲双胍/伏格列波糖降糖口服制剂组合物及其制备
CN102133402B (zh) * 2011-03-24 2013-06-12 首都医科大学附属北京同仁医院 囊性纤维化跨膜转导调节因子抑制剂在制备治疗糖尿病药物中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101189639B1 (ko) * 2008-12-15 2012-10-12 씨제이제일제당 (주) 메트포르민 및 α-글리코시다제 억제제를 포함하는 경구 제제 및 그 제조방법

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JEAN-LOUIS CHIASSON ET AL.: "The Synergistic Effect of Miglitol Plus Metform in Combination Therapy in the Treatment of Type 2 Diabetes.", CLINICAL CARE., vol. 24, no. 6, 1 June 2001 (2001-06-01), pages 989 - 994, XP055278094 *
See also references of EP2964211A4 *
SHI-DOU LIN ET AL.: "The beneficial effect of alpha-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwan ese type 2 diabetic patients inadequately controlled with metformin: preliminary data.", JOURNAL FOF DIABETES AND ITS COMPLICATIONS., vol. 25, no. 5, 20 June 2011 (2011-06-20), pages 332 - 338, XP028287519, DOI: 10.1016/J.JDIACOMP.2011.06.004 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026000747A1 (fr) * 2024-06-26 2026-01-02 四川大学华西医院 Système de prédiction de diabète et d'hypertension basé sur un signal électrique gastro-intestinal et procédé de construction

Also Published As

Publication number Publication date
KR101336499B1 (ko) 2013-12-03
BR112015018934A2 (pt) 2017-07-18
TW201434463A (zh) 2014-09-16
PH12014500736A1 (en) 2014-06-30
CN104027328A (zh) 2014-09-10
JP2016509065A (ja) 2016-03-24
EP2964211A4 (fr) 2016-08-31
EP2964211A1 (fr) 2016-01-13
HK1212587A1 (zh) 2016-06-17

Similar Documents

Publication Publication Date Title
WO2018030879A1 (fr) Composition pharmaceutique comprenant comme principes actifs de l'amodiaquine et un médicament anti-diabète, destinée à la prévention ou le traitement du diabète
EP2685997A2 (fr) Composition contenant un extrait d'une combinaison d'herbes utilisable en vue de la prévention ou du traitement de la neuropathie diabétique périphérique
WO2019221473A1 (fr) Composition pharmaceutique comprenant un inhibiteur de sglt-2 et un inhibiteur de dpp-iv
WO2014088326A1 (fr) Composition comprenant un inhibiteur de phosphodiestérase de type 5 pour l'inhibition d'apoptose de neurones
WO2019231220A1 (fr) Utilisation d'un composé thiophène 2,3,5-substitué pour prévenir, atténuer ou traiter des cancers du sein
WO2020045992A1 (fr) Composition destinée à éradiquer helicobacter pylori
WO2023182567A1 (fr) Peptide ayant une activité antidiabétique, complexe peptidique et son utilisation
WO2014137090A1 (fr) Préparation pour la prévention ou le traitement du diabète
WO2023101441A1 (fr) Utilisation d'un inhibiteur de protéine de transfert de triglycéride microsomale dans le traitement d'une maladie fibrotique
WO2014109587A1 (fr) Composition pharmaceutique et aliment fonctionnel comprenant des extraits naturels pour prévenir ou traiter les complications diabétiques ou l'angiodème
WO2016048005A2 (fr) Nouveau dérivé de pipéridine pentadiénoyl et son utilisation
WO2016209061A1 (fr) Préparation composite de mosapride et de rabéprazole
WO2022005201A1 (fr) Composition pour la prévention, l'amélioration ou le traitement des maladies provoquées par la nitration de la tyrosine dans une protéine contenant de la tyrosine comme principe actif
WO2023096446A1 (fr) Utilisation d'étravirine dans le traitement de maladies métaboliques et de maladies fibrotiques
WO2024144313A1 (fr) Composition pharmaceutique comprenant de l'énavogliflozine et de la metformine
WO2020204609A1 (fr) Composition pharmaceutique comprenant de l'esoméprazole ou un sel pharmaceutiquement acceptable de ce dernier, et présentant un profil à double libération
WO2024063568A1 (fr) Composition et polythérapie pour le traitement du diabète sucré de type 2
WO2024215162A1 (fr) Protéine de fusion unique et composition pharmaceutique la comprenant
WO2019139365A1 (fr) Nouveau dérivé d'oxazole phénylsulfonyle et son utilisation
WO2020130696A1 (fr) Composition comprenant un composé inhibant le cyp4a utilisé comme principe actif pour la prévention ou le traitement de maladies métaboliques
WO2026005463A1 (fr) Composition, combinaison et polythérapie pour traitement du diabète sucré de type 2
WO2023096448A1 (fr) Utilisation d'obatoclax dans le traitement de maladies métaboliques et fibrotiques
WO2018026150A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies neurodégénératives
WO2021054510A1 (fr) Composition destinée à prévenir et à traiter le cancer du sein contenant de la sélénopsammapline a en tant que principe actif
WO2022163971A1 (fr) Composition pharmaceutique composite pour le traitement d'une maladie du cerveau, comprenant un inhibiteur de cholinestérase et un antioxydant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14760276

Country of ref document: EP

Kind code of ref document: A1

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015018934

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2015559188

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2014760276

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014760276

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015/14066

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 112015018934

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150806